USANA Health Sciences stock reports a Q2 loss before October results

Published on 10/06/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

USANA Health Sciences stock posted USD 223.3 million in Q2 sales for the period ended July 4, 2026. Diluted EPS was negative USD 1.16 versus positive USD 0.52 a year earlier.

USNA, US90328M1071, Illustration mit AI erstellt.

USANA Health Sciences stock reported a second-quarter loss after the company generated USD 223.3 million in sales for the period ended July 4, 2026. USANA Health Sciences lists diluted EPS of negative USD 1.16 for Q2 2026, while its investor-relations page identifies the quarter as the latest reported period.

Q2 revenue falls 5.3 percent

The quarter ended July 4 brought USD 223.3 million in revenue, down 5.3 percent from USD 236.0 million in Q2 2025. Simply Wall St reported the comparison on October 1, 2026, and also cited diluted EPS of negative USD 1.16 versus positive USD 0.52 in the year-earlier quarter.

The earnings mix is important because the revenue decline and the earnings reversal point in the same direction. USANA's quarterly operating margin was negative 9 percent in Q2 2026, compared with positive 6 percent in Q1 2026, while operating cash flow remained positive at USD 23.3 million for the latest quarter.

October results set the next test

USANA's next scheduled quarterly report is October 28, 2026, covering Q3 2026. MarketBeat lists consensus EPS of USD 0.11 and expected revenue of USD 219.02 million for that report.

That expectation puts the next quarter below the USD 223.3 million recorded in Q2 2026. The comparison gives the October release a clear operational test: whether sales can stabilize while the company works through pressure in its nutrition and direct-to-consumer businesses.

USNA trades above its yearly low

USNA was last at USD 14.85 on the NYSE on October 5, 2026 at 4:00 p.m. ET, up 0.20 percent from the prior close. The price sits within the 52-week range of USD 12.57 to USD 38.32, while the market capitalization was USD 274.2 million and volume was 163,725 shares on the same date.

For investors, the key contrast is visible in the numbers: positive quarterly operating cash flow alongside negative net income and a 5.3 percent year-over-year sales decline. The October report will show whether the revenue base has begun to recover.